Lifecare ASA: Mandatory notification of trade

Reference is made to the stock exchange announcement published by Lifecare ASA (the "Company") on 30 May 2024, regarding the commencement of the subscription period in the partially underwritten rights issue (the "Rights Issue"). Teigland Eiendom AS has today exercised 2,623,948 subscription rights in the Rights Issue. Please see the attached PDMR-forms related to the exercise of subscription rights in the Rights Issue by a company closely associated with a primary insiders in the Company. About us Lifecare ASA is a clinical stage medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare's main focus is to bring the next generation of Continuous Glucose Monitoring ("CGM") systems to market. Lifecare enables osmotic pressure as sensing principle, combined with the ability to manipulate Nano-granular Tunnelling Resistive sensors ("NTR") on the sensor body for read-out of pressure variations. Lifecare's sensor technology is referred to as "Sencell" and is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets. Contacts For further information, please contact: Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40 Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42 This information is subject to disclosure under the Norwegian Securities Trading Act, §5-12. The information was submitted for publication at 2024-06-04 17:30 CEST.